Longbio Pharma (Suzhou) Co (HKSE:01779) ROCE %: -161.58% (As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$157.20
View Full Analysis

What is Longbio Pharma (Suzhou) Co ROCE %?

Longbio Pharma (Suzhou) Co HKSE:01779 +3.63% 10 ROCE % is -161.58% as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Longbio Pharma (Suzhou) Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -161.58%.

Longbio Pharma (Suzhou) Co  (HKSE:01779) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Longbio Pharma (Suzhou) Co ROCE % Related Terms

Longbio Pharma (Suzhou) Co ROCE % Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co ROCE % Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
ROCE %
-196.27 -161.58

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
ROCE % -196.27 -161.58
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co ROCE % Calculation

Longbio Pharma (Suzhou) Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-175.347/( ( (158.986 - 101.145) + (251.388 - 92.19) )/ 2 )
=-175.347/( (57.841+159.198)/ 2 )
=-175.347/108.5195
=-161.58 %

Longbio Pharma (Suzhou) Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=-175.347/( ( (158.986 - 101.145) + (251.388 - 92.19) )/ 2 )
=-175.347/( ( 57.841 + 159.198 )/ 2 )
=-175.347/108.5195
=-161.58 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -161.58% mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a ROCE % of -161.58% as of Dec. 2025.
Is Longbio Pharma (Suzhou) Co's ROCE % too high?
Longbio Pharma (Suzhou) Co's current ROCE % is -161.58%. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's ROCE % compare to ?
Longbio Pharma (Suzhou) Co's ROCE % of -161.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Longbio Pharma (Suzhou) Co's current ROCE % is -161.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current ROCE % of -161.58%. The current ROCE % is -161.58%. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current ROCE % is -161.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$157.20
Price